Summary
Remifentanil is a novel, short-acting μ-receptor opioid agonist currently in the late stages of development. A member of the 4-anilidopiperidine class, it is unique among the currently marketed agents because of its ester structure. Remifentanil undergoes widespread extrahepatic metabolism by blood and tissue nonspecific esterases, resulting in an extremely rapid clearance of approximately 3 L/min (180 L/h). Like the other members of this class of drugs, remifentanil is lipophilic and is widely distributed in body tissues with a steady-state volume of distribution of approximately 30L.
Because of its unique metabolic pathway (among this group of drugs) and rapid clearance, remifentanil represents a new pharmacokinetic class of opioid. Unlike the other fentanyl congeners, termination of the therapeutic effect of remifentanil mostly depends on metabolic clearance rather than on redistribution. The context-sensitive half-time [defined as the time necessary to achieve a 50% decrease in blood (or plasma) concentration after termination of a variable-length, continuous infusion targeted to maintain a steady-state concentration, where the ‘context’ is the duration of the infusion] is strikingly short for remifentanil, and this is perhaps the most compelling evidence of the pharmacokinetic singularity of the drug. Determined by computer simulation, the context-sensitive half-time of remifentanil is approximately 3 minutes, and is independent of infusion duration.
Pharmacodynamically, remifentanil is similar to the other fentanyl congeners. The drug produces physiological changes consistent with potent γ-receptor agonist activity, including analgesia and sedation. Its adverse effect profile (like that of the other drugs of this class) includes ventilatory depression, nausea, vomiting, muscular rigidity, bradycardia and pruritus. Because it does not release histamine upon injection, remifentanil has fewer haemodynamic adverse effects than morphine. The therapeutic potency of remifentanil is somewhat less than that of fentanyl, with an effective concentration (producing 50% of maximal effect, as measured by electroencephalography) of approximately 15 to 20 µg/L. Speed of onset of effect is very rapid and is similar to that of alfentanil, which is reflected in a t1/2 ke0(a parameter used to characterise the delay between peak blood drug concentration and peak pharmacodynamic effect utilising a theoretical effect compartment) of approximately 1 to 2 minutes.
Remifentanil is likely to be a welcome addition to the anaesthesia drug formulary. Anaesthetists have long recognised the need for a short-acting opioid with a predictable pharmacokinetic profile. Because the length of surgical procedures is often unpredictable, and because the level of surgical stimulation against which the depth of anaesthesia must be balanced is highly variable and dynamic, the advantages of predictably short-acting agents are obvious.
Similar content being viewed by others
References
Feldman PL, James MK, Brackeen MF, et al. Design, synthesis, and pharmacological evaluation of ultrashort to long acting opioid analgetics. J Med Chem 1991; 34: 2202–8
Data on file, Glaxo, Research Triangle Park, NC, USA
Grosse CM, Davis IM, Arrendal RF, et al. Determination of remifentanil in human blood by liquid-liquid extraction and capillary GC-HRMS-SIM using a deuterated internal standard. J Pharm Biomed Anal 1994; 12(2): 195–203
Selinger K, Lanzo C, Sekut A. Determination of remifentanil in human and dog blood by HPLC with UV detection. J Pharm Biomed Anal 1994; 12(2): 243–8
Glass PSA, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short acting opioid: remifentanil (GI87084B). Anesth Analg 1993; 77: 1031–40
Egan TD, Lemmens HJM, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 1993; 79: 881–92
Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993; 79: 893–903
Egan TD, Lemmens HJM, Fiset P, et al. The pharmacokinetics and pharmacodynamics of GI87084B [abstract]. Anesthesiology 1992; 77: A369
Egan TD, Minto C, Lemmens HJM, et al. Remifentanil versus alfentanil: comparative pharmacokinetics [abstract]. Anesthesiology 1994; 81: A373
Benet LZ. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci 1972; 61: 536–41
Beal SL, Sheiner LB. NONMEM User’s Guide. San Francisco: University of California at San Francisco, 1979
Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240: 159–66
Rosow C. Remifentanil: a unique opioid analgesic [editorial]. Anesthesiology 1993; 79: 875–6
Dershwitz M, Rosow CE, Michalowski P, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease compared with normal subjects [abstract]. Anesthesiology 1994; 81: A377
Hoke J, Muir K, Glass P, et al. Pharmacokinetics of remifentanil and its metabolite (GI90291) in subjects with renal disease [abstract]. Clin Pharmacol Ther 1995; 57: PI55
Shlugman D, Dufore S, Dershwitz M, et al. Respiratory effects of remifentanil in subjects with severe renal impairment compared to matched controls [abstract]. Anesthesiology 1994; 81: A1417
Gupta S, Haigh A, Kenny G, et al. The pharmacokinetics of remifentanil injection during hypothermic cardiopulmonary bypass in humans. Proceedings of the 16th Annual Meeting of the Society of Cardiovascular Anesthesiologists; 1994 Apr 23–27: Montreal, Canada
Egan TD, Gambus P, Billard V, et al. Gender has no effect on the pharmacokinetics or pharmacodynamics of remifentanil [abstract]. Anesthesiology. In press
Hughes MA, Glass PSA, Jacobs JR. Context-sensitive halftimes in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1991; 76: 334–41
Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics and rational opioid selection. Anesthesiology 1991; 74:53–63
Kapila A, Muir KT, Hermann DJ, et al. Measured context sensitive half-times of remifentanil and alfentanil [abstract]. Anesthesiology 1993; 79: A377
James MK, Feldman PL, Schuster SV, et al. Opioid receptor activity of GI87084B, a novel ultra-short acting analgesic, in isolated tissues. J Pharmacol Exp Ther 1991; 259(2): 712–8
Amin HM, Sopchak AM, Esposito BF, et al. Naloxone reversal of depressed ventilatory response to hypoxia during continuous infusion of remifentanil [abstract]. Anesthesiology 1993; 79: A1203
Hoffman WE, Cunningham F, James MK, et al. Effects of remifentanil, a new short-acting opioid, on cerebral blood flow, brain electrical activity, and intracranial pressure in dogs anesthetized with isoflurane and nitrous oxide. Anesthesiology 1993; 79: 107–13
Cunningham FE, Hoffman WE, Baughman VL. Comparative pharmacodynamics of remifentanil, a new short acting opioid, GI90921A the active metabolite and alfentanil [abstract]. Anesthesiology 1993; 79: A712
Egan TD, Minto C, Lemmens HJM, et al. Remifentanil versus alfentanil: comparative pharmacodynamics [abstract]. Anesthesiology 1994; 81: A374
Salmenpera M, Wilson D, Szlam F, et al. Anesthetic potency of the opioid GI87084B in dogs [abstract]. Anesthesiology 1992; 77: A368
Kapila A, Lang E, Glass P, et al. MAC reduction of isoflurane by remifentanil [abstract]. Anesthesiology 1994; 81: A378
Randel GI, Fragen RJ, Librojo ES, et al. Remifentanil blood concentration effect relationship at intubation and skin incision in surgical patients compared to alfentanil [abstract]. Anesthesiology 1994; 81: A375
James MK, Vuong A, Grizzle MK, et al. Hemodynamic effects of GI 87084B, an ultra-short acting mu-opioid analgesic, in anesthetized dogs. J Pharmacol Exp Ther 1992; 263(1): 84–91
Pitts MC, Palmore MM, Salmenpera MT, et al. Pilot study: hemodynamic effects of intravenous GI87084B in patients undergoing elective surgery [abstract]. Anesthesiology 1992; 77: A101
Reitan JA, Stengert KB, Wymore ML, et al. Central vagal control of fentanyl-induced bradycardia during halothane anesthesia. Anesth Analg 1978; 57: 31–6
Sebel PS, Hoke JF, Westmoreland C, et al. Histamine concentrations and hemodynamic responses release after remifentanil. Anesth Analg 1995; 80: 990–3
Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982; 56: 93–6
Joshi P, Jhaveri R, Bauman V, et al. Comparative trial of remifentanil and alfentanil for anesthesia induction [abstract]. Anesthesiology 1993; 79: A379
Streisand JB, Bailey PL, Lemaire L, et al. Fentanyl-induced rigidity and unconsciousness in human volunteers. Anesthesiology 1993; 78: 629–34
Mather LE. Pharmacokinetic and pharmacodynamic profiles of opioid analgesics: a sameness amongst equals? [editorial]. Pain 1990; 43: 3–6
Shafer SL, Stanski DR. Improving the clinical utility of anesthetic drug pharmacokinetics. Anesthesiology 1992; 76: 327–30
Kallar SK, Hurt TW, Wetchler BV, et al. A single blind, comparative study of the safety and efficacy of remifentanil and alfentanil for outpatient anesthesia [abstract]. Anesthesiology 1994; 81: A32
Fragen RJ, Randel GI, Librojo ES, et al. The interaction of remifentanil and propofol to prevent response to tracheal intubation and the start of surgery for outpatient knee arthroscopy [abstract]. Anesthesiology 1994; 81: A376
Johnstone RE, Jozefczyk KG. Costs of anesthetic drugs: experiences with a cost education trial. Anesth Analg 1994; 78: 766–71
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Egan, T.D. Remifentanil Pharmacokinetics and Pharmacodynamics. Clin. Pharmacokinet. 29, 80–94 (1995). https://doi.org/10.2165/00003088-199529020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199529020-00003